Novo A/S leads $45 mln Series C funding round in Spinifex Pharmaceuticals
Novo A/S has led a $45 million Series C funding round in Spinifex Pharmaceuticals, a developer of pain drugs. The funding round was joined by new investor Canaan Partners. Existing investors GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest also participated in the funding round. Heath Lukatch and Steve Collins representing Novo A/S and Brent Ahrens of Canaan Partners will join the Spinifex board.
11 April 2014•4 mins read
